Apaxis

Apaxis is a medical technology company specializing in advanced drug delivery systems for pulmonary arterial hypertension (PAH). The company's primary innovation is an implantable, refillable pump designed for the continuous delivery of treprostinil, a prostacyclin analogue marketed as Remodulin. This technology seeks to provide a more convenient and less painful alternative to external infusion pumps, which are the current standard of care and often cause significant site pain. Following its acquisition by United Therapeutics in 2023, the technology is being advanced as part of the RemoPro program to enhance the lives of patients requiring prostacyclin therapy. The system is currently undergoing clinical evaluation to support regulatory approval.